Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

PubWeight™: 4.60‹?› | Rank: Top 1%

🔗 View Article (PMC 4151302)

Published in Circulation on December 17, 2013

Authors

Sumeet S Chugh1, Rasmus Havmoeller, Kumar Narayanan, David Singh, Michiel Rienstra, Emelia J Benjamin, Richard F Gillum, Young-Hoon Kim, John H McAnulty, Zhi-Jie Zheng, Mohammad H Forouzanfar, Mohsen Naghavi, George A Mensah, Majid Ezzati, Christopher J L Murray

Author Affiliations

1: Cedars-Sinai Heart Institute, Los Angeles, CA (S.S.C., R.H., K.N., D.S.); Karolinska Institute, Stockholm, Sweden (R.H.); University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (M.R.); Framingham Heart Study and Boston University School of Medicine and Public Health, Boston, MA (E.J.B.); Department of Medicine, Howard University College of Medicine, Washington, DC (R.F.G.); Korea University College of Medicine, Seoul, Republic of Korea (Y.-H.K.); Legacy Good Samaritan Medical Center, Portland, OR (J.H.M.); National Heart, Lung, and Blood Institute, Bethesda, MD (Z.-J.Z., G.A.M.); Institute for Health Metrics and Evaluation, University of Washington, Seattle (M.H.F., M.N., C.J.L.M.); and Harvard School of Public Health, Boston, MA (M.E.).

Associated clinical trials:

The Substrate and Intervention Mechanisms for Persistent Atrial Fibrillation Trial (SIMPle-AF) | NCT02918396

Atrial Fibrillation Lifestyle Project (ALP) | NCT03724383

Lifestyle Modification for the Treatment of Symptomatic Atrial Fibrillation (LIFE-AF) (LIFE-AF) | NCT03785418

Systematic Evaluation of Ablation Techniques for Non-Paroxysmal Atrial Fibrillation. (PLEA) | NCT04216667

Clinical and Economic Impact of an Organized Treatment Pathway on AFib Patient Management From the ER (ER2EP) | NCT04476524

Epigenetic Analysis of Regulation of the Inflammasome-activating NLRP3 Gene in Monocytes From Atrial Fibrillation Patients and Controls | NCT04766814

ABLATE Versus PACE: PVI or AV Node Ablation and PM Implantation for Elderly Patients With Persistent AF | NCT04906668

Evaluating Quality of Life of AF Patients Following a Bleed (EQUAL-AF) | NCT04921176

Articles citing this

(truncated to the top 100)

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 14.88

Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA (2014) 3.59

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet (2015) 3.02

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (2015) 2.83

Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76

National Trends in Ambulatory Oral Anticoagulant Use. Am J Med (2015) 1.41

Ablation of atrial fibrillation. Trends Cardiovasc Med (2014) 1.41

Central Sleep-disordered Breathing Predicts Incident Atrial Fibrillation in Older Men. Am J Respir Crit Care Med (2016) 1.39

Left Atrial LGE and Arrhythmia Recurrence Following Pulmonary Vein Isolation for Paroxysmal and Persistent AF. JACC Cardiovasc Imaging (2016) 1.39

Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol (2014) 1.39

Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm (2014) 1.25

Lone atrial fibrillation: does it exist? J Am Coll Cardiol (2014) 1.21

Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. EMBO Mol Med (2015) 1.08

Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. Neuroepidemiology (2015) 1.02

Genetic Obesity and the Risk of Atrial Fibrillation- Causal Estimates from Mendelian Randomization. Circulation (2016) 1.00

Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc (2015) 0.99

Genetics of atrial fibrillation: from families to genomes. J Hum Genet (2015) 0.96

Mechanisms for the Termination of Atrial Fibrillation by Localized Ablation: Computational and Clinical Studies. Circ Arrhythm Electrophysiol (2015) 0.96

EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. J Arrhythm (2016) 0.94

Anticoagulation in atrial fibrillation. BMJ (2014) 0.93

Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis. PLoS Med (2016) 0.91

Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. Medicine (Baltimore) (2015) 0.90

Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol (2016) 0.89

Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS One (2015) 0.88

Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. Stroke (2016) 0.87

Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol (2015) 0.87

Atrial fibrillation in heart failure: what should we do? Eur Heart J (2015) 0.86

Lone Atrial Fibrillation Is Associated With Impaired Left Ventricular Energetics That Persists Despite Successful Catheter Ablation. Circulation (2016) 0.85

Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. JAMA Cardiol (2016) 0.84

Evaluation of the Association Between Retinal Vein Occlusion and the Risk of Atrial Fibrillation Development: A 12-Year, Retrospective Nationwide Cohort Study. Sci Rep (2016) 0.82

Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep (2016) 0.82

Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clin J Am Soc Nephrol (2016) 0.82

Atrial fibrillation is associated with hematopoietic tissue activation and arterial inflammation. Int J Cardiovasc Imaging (2015) 0.82

A rising tide: the global epidemic of atrial fibrillation. Circulation (2013) 0.82

The AFFORD clinical decision aid to identify emergency department patients with atrial fibrillation at low risk for 30-day adverse events. Am J Cardiol (2015) 0.81

The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord (2014) 0.81

Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: the Look AHEAD randomized trial. Am Heart J (2015) 0.81

Mechanistically based mapping of human cardiac fibrillation. J Physiol (2016) 0.81

Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly. Circulation (2015) 0.81

Prediction and personalised treatment of atrial fibrillation-stroke prevention: consolidated position paper of CVD professionals. EPMA J (2014) 0.81

Rationale and design of the Chinese Atrial Fibrillation Registry Study. BMC Cardiovasc Disord (2016) 0.81

Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. J Am Heart Assoc (2016) 0.81

Non-Pharmacologic Approach to Prevent Embolization in Patients with Atrial Fibrillation in Whom Anticoagulation is Contraindicated. Clin Pract (2017) 0.80

Intermittent drivers anchoring to structural heterogeneities as a major pathophysiological mechanism of human persistent atrial fibrillation. J Physiol (2016) 0.80

Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. Chest (2015) 0.80

Prevalence of atrial fibrillation in an urban population in India: the Nagpur pilot study. Heart Asia (2016) 0.80

The Future of Arrhythmias and Electrophysiology. Circulation (2016) 0.79

Atrial remodelling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal. Cardiovasc Res (2016) 0.79

Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. BMJ Open (2015) 0.79

Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: a population-based study. J Am Heart Assoc (2015) 0.79

30-Year Trends in Stroke Rates and Outcome in Auckland, New Zealand (1981-2012): A Multi-Ethnic Population-Based Series of Studies. PLoS One (2015) 0.79

Preoperative heart rate and myocardial injury after non-cardiac surgery: results of a predefined secondary analysis of the VISION study. Br J Anaesth (2016) 0.78

Left atrial appendage closure devices. Clin Med Insights Cardiol (2014) 0.78

A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am Heart J (2016) 0.78

LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation. Cardiovasc Res (2015) 0.78

Role of neural modulation in the pathophysiology of atrial fibrillation. Indian J Med Res (2014) 0.78

Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants. Arrhythm Electrophysiol Rev (2014) 0.78

Comparison of Detailed and Simplified Models of Human Atrial Myocytes to Recapitulate Patient Specific Properties. PLoS Comput Biol (2016) 0.78

Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis. Medicine (Baltimore) (2015) 0.77

Left Atrial and Left Atrial Appendage 4D Blood Flow Dynamics in Atrial Fibrillation. Circ Cardiovasc Imaging (2016) 0.77

Organized Sources Are Spatially Conserved in Recurrent Compared to Pre-Ablation Atrial Fibrillation: Further Evidence for Non-Random Electrical Substrates. J Cardiovasc Electrophysiol (2016) 0.77

Atrial fibrillation: prevalence in a large database of primary care patients in Brazil. Europace (2015) 0.77

Making better scar: Emerging approaches for modifying mechanical and electrical properties following infarction and ablation. Prog Biophys Mol Biol (2015) 0.77

Defining the role of oxidative stress in atrial fibrillation and diabetes. J Cardiovasc Electrophysiol (2014) 0.77

The Prevalence and Incidence of Atrial Fibrillation in Patients with Acute Pulmonary Embolism. PLoS One (2016) 0.77

Atrial Fibrillation, Cognitive Decline And Dementia. Eur Cardiol (2016) 0.77

Epidemiology, diagnosis, and management of atrial fibrillation in women. Int J Womens Health (2015) 0.77

The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation. J Stroke (2016) 0.77

PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers. J Am Coll Cardiol (2016) 0.77

Three-dimensional left atrial blood flow characteristics in patients with atrial fibrillation assessed by 4D flow CMR. Eur Heart J Cardiovasc Imaging (2015) 0.77

MMP9 Rs3918242 Polymorphism Affects Tachycardia-Induced MMP9 Expression in Cultured Atrial-Derived Myocytes but Is Not a Risk Factor for Atrial Fibrillation among the Taiwanese. Int J Mol Sci (2016) 0.77

Left Atrial 4-Dimensional Flow Magnetic Resonance Imaging: Stasis and Velocity Mapping in Patients With Atrial Fibrillation. Invest Radiol (2016) 0.77

Predicting Atrial Fibrillation and Its Complications. Circ J (2016) 0.77

Association of genetic variants with atrial fibrillation. Biomed Rep (2015) 0.77

Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing. BMC Cardiovasc Disord (2016) 0.76

Sex-Based Differences in Cardiometabolic Biomarkers. Circulation (2017) 0.76

Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol (2015) 0.76

Probucol prevents atrial ion channel remodeling in an alloxan-induced diabetes rabbit model. Oncotarget (2016) 0.76

Major themes for 2013 in cardiothoracic and vascular anaesthesia and intensive care. Heart Lung Vessel (2014) 0.76

Biological Therapies for Atrial Fibrillation: Ready for Prime Time? J Cardiovasc Pharmacol (2016) 0.76

Association of Increased Epicardial Adipose Tissue Thickness With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation. Medicine (Baltimore) (2016) 0.76

Up-regulation of miR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase. Sci Transl Med (2016) 0.76

Identification of rare variants in TNNI3 with atrial fibrillation in a Chinese GeneID population. Mol Genet Genomics (2015) 0.76

The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight? J Cardiovasc Pharmacol (2016) 0.76

Prevalence and Spectrum of TBX5 Mutation in Patients with Lone Atrial Fibrillation. Int J Med Sci (2016) 0.76

Atrial fibrillation in the Indigenous populations of Australia, Canada, New Zealand, and the United States: a systematic scoping review. BMC Cardiovasc Disord (2015) 0.76

Efficacy of Short-Term Antiarrhythmic Drugs Use after Catheter Ablation of Atrial Fibrillation-A Systematic Review with Meta-Analyses and Trial Sequential Analyses of Randomized Controlled Trials. PLoS One (2016) 0.76

Catheter ablation versus anti-arrhythmic drug therapy for the management of a trial fibrillation: a meta-analysis. J Interv Card Electrophysiol (2014) 0.75

The Predictive Role of Inflammatory Biomarkers in Atrial Fibrillation as Seen through Neutrophil-Lymphocyte Ratio Mirror. J Biomark (2016) 0.75

Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral-Anticoagulation-Naïve Patients With Atrial Fibrillation: A Randomized Trial. J Am Heart Assoc (2016) 0.75

Postoperative metabolic acidosis following the minimally invasive radiofrequency maze procedure. Ann Card Anaesth (2016) 0.75

Warfarin treatment and risk of myocardial infarction - A cohort study of patients with atrial fibrillation treated in primary health care. Int J Cardiol (2016) 0.75

A Treatment Planning Study of Stereotactic Body Radiotherapy for Atrial Fibrillation. Cureus (2016) 0.75

Editorial: Cardiac electronic remodeling and susceptibility to arrhythmias: an introduction and brief historical overview. Front Physiol (2015) 0.75

The risk of atrial fibrillation in patients with gout: a nationwide population-based study. Sci Rep (2016) 0.75

Oral carvedilol in escalating doses in the acute treatment of atrial fibrillation. J Pharmacol Pharmacother (2014) 0.75

An endocrine hypothesis for the genesis of atrial fibrillation: the hypothalamic-pituitary-adrenal axis response to stress and glycogen accumulation in atrial tissues. N Am J Med Sci (2014) 0.75

Modern treatment of atrial fibrillation. Korean J Thorac Cardiovasc Surg (2014) 0.75

Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. Tex Heart Inst J (2016) 0.75

Hybrid contact force ablation: best of both worlds? Neth Heart J (2015) 0.75

Articles cited by this

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 50.94

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 44.03

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (2006) 37.83

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 25.40

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA (2001) 24.12

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 19.93

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80

GBD 2010: design, definitions, and metrics. Lancet (2012) 8.64

Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83

Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol (1998) 6.76

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31

Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol (1994) 4.08

Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol (2001) 3.83

Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes (2011) 3.25

Modeling causes of death: an integrated approach using CODEm. Popul Health Metr (2012) 3.12

Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart (2001) 2.78

Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation (2011) 2.63

Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes (2012) 2.61

Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart (2004) 2.56

Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J (1996) 2.47

Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J (2005) 2.28

Quality of life in patients with atrial fibrillation: a systematic review. Am J Med (2006) 2.17

European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation (2010) 1.90

Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ (2008) 1.35

A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail (2009) 1.24

The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health (2007) 1.05

Atrial fibrillation--the growing epidemic. Heart (2007) 1.05

Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc (1996) 0.96

Incident atrial fibrillation and mortality in older adults with heart failure. Eur J Heart Fail (2005) 0.91

What are the costs of atrial fibrillation? Europace (2011) 0.89

Articles by these authors

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 50.94

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (2006) 37.83

Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet (2010) 33.69

Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98

Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95

Maternal and child undernutrition: global and regional exposures and health consequences. Lancet (2008) 26.44

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet (2011) 24.73

Selected major risk factors and global and regional burden of disease. Lancet (2002) 24.47

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation (2003) 23.97

Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74

Household catastrophic health expenditure: a multicountry analysis. Lancet (2003) 20.07

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet (2011) 19.21

Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet (2013) 18.02

Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet (2012) 17.62

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet (2013) 16.76

Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25

Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72

Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysis. Lancet (2011) 14.16

Financing of global health: tracking development assistance for health from 1990 to 2007. Lancet (2009) 13.41

Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39

Obesity and the risk of heart failure. N Engl J Med (2002) 12.58

Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet (2010) 12.28

The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med (2009) 12.13

Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32

Public financing of health in developing countries: a cross-national systematic analysis. Lancet (2010) 11.22

The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43

Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14

Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06

The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90

Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80

Eight Americas: investigating mortality disparities across races, counties, and race-counties in the United States. PLoS Med (2006) 8.70

GBD 2010: design, definitions, and metrics. Lancet (2012) 8.64

Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49

Fine-particulate air pollution and life expectancy in the United States. N Engl J Med (2009) 8.36